ClinicalTrials.gg
CompletedNCT00635817Updated Nov 2, 2011Results posted

A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty

A Phase 3 interventional study of Leuprolide acetate 11.25 mg and Leuprolide acetate 30 mg in Puberty, Precocious, sponsored by Abbott. Completed at 25 sites in 2 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2011-11-02.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
2 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing leuprolide in Puberty, Precocious — 2 open to participants now, 2 under way, 1 of them phase 3. Leuprolide · Puberty, Precocious.

Enrollment
5th of 14
84 · median 68
Started
2008
with 1 other
Phase 3
6 of 14
1 open now
Registered
1st of 14
by date
Lead sponsor
2 of 14
Abbott

Among the 14 studies testing leuprolide in Puberty, Precocious, this one is the 5th largest by enrollment, is one of 2 that started in 2008, is one of 6 in phase 3, and was the 1st registered.

Puberty, Precocious

75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.

Browse Puberty, Precocious studies →

Open to participants now

2 of the 14 studies testing leuprolide in Puberty, Precocious are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 2 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing leuprolide in Puberty, Precocious, or all of them as a file.
02

Study summary

The purpose of this study is to determine if 11.25 and 30 mg formulations of leuprolide are effective in treating children with Central Precocious Puberty (CPP).

Read the detailed description

Study Design:

A total of 80 children with confirmed CPP were planned to be enrolled and randomized in a 1:1 ratio to receive 2 injections of either leuprolide acetate 11.25 mg or 30 mg depot formulation, each injection administered 3 mo apart (6 mo of treatment):

This study includes a 4-week Screening Period, two 3-mo treatment cycles, and a posttreatment follow-up period (12 weeks following the Mo 6 visit). Study visits will occur at Screening, Day 1, Week 2 (only for subjects participating in the pharmacokinetic subset), Mo 1, 2, 3, Mo 6/Early Termination, and 12 weeks later, for the Posttreatment Follow-up Visit.

This study was conducted at 18 sites in the United States and 4 sites in Puerto Rico.

03

Conditions studied

  • Puberty, Precocious

Browse trials for

Keywords

  • CPP
  • central precocious puberty
  • pediatrics
  • suppression of luteinizing hormone
  • Lupron
  • leuprolide acetate
  • depot formulation
  • GnRHa
  • GnRH agonist
  • GnRH analog
  • luteinizing hormone
04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a clinical diagnosis of CPP.
  • Eligible to receive at least 6 mo of therapy to treat CPP after study entry.
  • Bone age advanced at least 1 year beyond the chronological age at time of diagnosis or first treatment.
  • In general good health with no uncontrolled, disease which would interfere with bone maturation or mask the objectives of this protocol as assessed by the investigator.

Additional criteria for subjects who have not had previous treatment:

  • Girls 2-8 years inclusive or Boys 2-9 years inclusive at Day 1.
  • Has pretreatment pubertal response to leuprolide acetate stimulation (luteinizing hormone ≥8 mIU/mL) at Screening.
  • Breast pubertal staging of at least 2 in girls; testicular volume of at least 4 cc or testicular length greater than 2.5 cm in boys at Screening.

Additional criteria for subjects previously treated:

  • Girls 2-10 years inclusive or boys 2-11 years inclusive at Day 1.
  • Must have been on standard gonadotropin releasing hormone analog therapy for at least the 6 mo prior to Day 1.
  • Has documented maintenance of luteinizing hormone suppression as evidenced by peak stimulated level \<4 mIU/mL at Screening.

Exclusion criteria

Exclusion Criteria:

  • Incomplete precocious puberty (premature thelarche, premature adrenarche).
  • Peripheral precocious puberty: gonadal or adrenal tumors, congenital adrenal hyperplasia, testotoxicosis in boys, human chorionic gonadotropin secreting tumor or McCune-Albright syndrome in girls.
  • Evidence of any abnormal pituitary, hypothalamic, adrenal, thyroid and gonadal function other than premature secretion of gonadotropins not adequately controlled.
  • Unstable intracranial tumors (unresponsive to treatment/expanding) except hamartoma.
  • Previous treatment with GnRHa therapy requiring leuprolide acetate for depot suspension >15 mg monthly.
  • Bone age >13 years for girls and >14 years for boys.
  • Any other condition interfering with growth, ie, skeletal dysplasia, cerebral palsy.
  • Chronic illness requiring treatment that may interfere with growth, ie, chronic use, renal failure, moderate to severe scoliosis.
  • Diagnosis of short stature, ie more than 2.25 standard deviations below the mean height for age (growth chart measurement).
  • Prior or current therapy with medroxyprogesterone acetate or growth hormone.
  • Has an abnormal laboratory value suggesting a underlying disease .
  • Creatinine >1.5 mg/dL, and/or aspartate aminotransferase >2.0 x , or total >2.0 mg/dL with aspartate aminotransferase/alanine aminotransferase elevated above normal limits.
  • Positive pregnancy test.
  • Known to study medication or its .
  • Participation in another drug research within 3 mo of enrollment into this study.
  • Prior or current therapy with insulin-like growth factor-1.
  • Use of an estrogen preparation within 2 mo prior to Day 1.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Leuprolide acetate 11.25 mg

    There are 2 arms that received leuprolide acetate 11.25 mg. Subjects who are treatment naive to leuprolide acetate are designated to be in Arm A and subjects who have previously been treated with leuprolide acetate are designated to be in Arm B.

    Drug: Leuprolide acetate 11.25 mg

  • Experimental
    Leuprolide acetate 30 mg

    There are 2 arms that received leuprolide acetate 30 mg. Subjects who are treatment naive to leuprolide acetate are designated to be in Arm C and subjects who have previously been treated with leuprolide acetate are designated to be in Arm D.

    Drug: Leuprolide acetate 30 mg

Interventions

  • Two intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 mo apart.

    Also known as: ABT-818, leuprolide acetate, Lupron

  • Two intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 mo apart.

    Also known as: ABT-818, leuprolide acetate, Lupron

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Suppression of Peak Stimulated Luteinizing Hormone (<4 mIU/mL) From Month 2 Through Month 6

    Percentage of participants with suppression of peak stimulated luteinizing hormone that was measured after a gonadotropin-releasing hormone agonist (GnRHa) stimulation test at Month (Mo) 2, 3, and 6. The analysis was performed according to a life table method. Subjects who withdrew without peak-stimulated luteinizing hormone \>= 4 mIU/mL were censored at their last measurement of peak-stimulated luteinizing hormone.

    Time frame: Month 2 through 6

Secondary outcomes

  1. Percentage of Participants With Suppression of Basal Estradiol <20 pg/mL by Visit

    Percentage of participants with suppression of estradiol, out of the number of girls with at least 1 estradiol measurement at each visit (n/N%). Only girls are analyzed in this outcome measure. Observed data were used with no imputation for missing data.

    Time frame: Month 1, 2, 3 and 6

  2. Percentage of Participants With Suppression of Testosterone in <30 ng/dL by Visit

    Percentage of participants with suppression of testosterone, out of the number of boys with at least 1 testosterone measurement at each visit (n/N%). Only boys are analyzed in this outcome measure. Observed data were used with no imputation for missing data.

    Time frame: Month 1, 2, 3 and 6

  3. Peak-stimulated Luteinizing Hormone Concentration by Visit

    Observed data were used with no imputation for missing data.

    Time frame: Baseline, Month 1, 2, 3 and 6

  4. Percentage of Participants With Suppression of the Physical Signs of Puberty (Breast Development) at Month 6

    Percentage of participants with suppression of breast development, out of the number of girls with pubertal staging of breast development (n/N%). Only girls are analyzed in this outcome measure. Breast development was rated from Stage 1 (early development) through Stage 5 (full development) according to a Tanner Staging pictogram. Girls entering the study with fully developed breasts (Stage 5) were excluded from this analysis. Observed data were used with no imputation for missing data.

    Time frame: Month 6

  5. Percentage of Participants With Suppression of the Physical Signs of Puberty (Testicular Volume and Genital Development) at Month 6

    Percentage of participants with suppression of genital development and testicular volume, out of the number of boys with pubertal staging of genital development or testicular volume (n/N%). Only boys are analyzed in this outcome measure. External genital development (testes and penis) was rated from Stage 1 (early development) through Stage 5 (full development) according to a Tanner Staging pictogram. Boys entering the study with fully developed genitals (Stage 5) were excluded from this analysis. Observed data were used with no imputation for missing data.

    Time frame: Month 6

  6. Change From Baseline in Incremental Growth Rate (cm/Year) at Month 6

    The growth rate at baseline was the growth rate during the last year before the start of treatment and was calculated with the measurement closest to Day -336 (before Day -30) and the measurement up to Day 1. Growth rate at Month 6 was defined as the ratio of the change in height from Day 1 to the change in chronological age, with an approximate 6-month interval between the 2 height measurements. Observed data were used with no imputation for missing data.

    Time frame: Baseline and Month 6

  7. Ratio of Change From Baseline in Bone Age/Change From Baseline in Chronological Age at Month 6

    The ratio at Month 6 was calculated as (bone age at Month 6 - bone age at baseline)/(chronological age at Month 6 - chronological age at baseline). Observed data were used with no imputation for missing data. Baseline bone-age radiograph was performed at or within 3 months of the Screening Visit.

    Time frame: Baseline to Month 6

07

Results

Posted Feb 9, 2011

Participant flow

Eighteen sites in the US and 4 sites in Puerto Rico enrolled subjects into the study. The first subject was randomized 17 June 2008 and the last subject was randomized 12 Aug 2009.

Participant flow — Overall Study
MilestoneLeuprolide Acetate 11.25 mg - Treatment NaiveLeuprolide Acetate 11.25 mg - Previous TreatmentLeuprolide Acetate 30 mg - Treatment NaiveLeuprolide Acetate 30 mg - Previous Treatment
Started21212121
Completed15191921
Not completed6220

Outcome measures

PrimaryPercentage of Participants With Suppression of Peak Stimulated Luteinizing Hormone (<4 mIU/mL) From Month 2 Through Month 6

Percentage of participants with suppression of peak stimulated luteinizing hormone that was measured after a gonadotropin-releasing hormone agonist (GnRHa) stimulation test at Month (Mo) 2, 3, and 6. The analysis was performed according to a life table method. Subjects who withdrew without peak-stimulated luteinizing hormone \>= 4 mIU/mL were censored at their last measurement of peak-stimulated luteinizing hormone.

Time frame:
Month 2 through 6
Reported as:
Number · Percentage of Participants
Percentage of Participants With Suppression of Peak Stimulated Luteinizing Hormone (<4 mIU/mL) From Month 2 Through Month 6
Percentage of ParticipantsLeuprolide Acetate 11.25 mg - Treatment NaiveLeuprolide Acetate 11.25 mg - Previous TreatmentLeuprolide Acetate 30 mg - Treatment NaiveLeuprolide Acetate 30 mg - Previous Treatment
Percentage of Participants With Suppression of Peak Stimulated Luteinizing Hormone (<4 mIU/mL) From Month 2 Through Month 676.2 ± 9.2980.7 ± 8.6990.5 ± 6.41100 ± 0.00
SecondaryPercentage of Participants With Suppression of Basal Estradiol <20 pg/mL by Visit

Percentage of participants with suppression of estradiol, out of the number of girls with at least 1 estradiol measurement at each visit (n/N%). Only girls are analyzed in this outcome measure. Observed data were used with no imputation for missing data.

Time frame:
Month 1, 2, 3 and 6
Reported as:
Number · Percentage of Participants
Percentage of Participants With Suppression of Basal Estradiol <20 pg/mL by Visit
Percentage of ParticipantsLeuprolide Acetate 11.25 mg - Treatment NaiveLeuprolide Acetate 11.25 mg - Previous TreatmentLeuprolide Acetate 30 mg - Treatment NaiveLeuprolide Acetate 30 mg - Previous Treatment
Mo 1 (Arm A N=17, B N=18, C N=19, D N=16)100 (80.5 to 100)100 (81.5 to 100)100 (82.4 to 100)100 (79.4 to 100)
Mo 2 (Arm A N=19, B N=14, C N=19, D N=14)94.7 (74.0 to 99.9)100 (76.8 to 100)100 (82.4 to 100)100 (76.8 to 100)
Mo 3 (Arm A N=15, B N=18, C N=17, D N=18)100 (78.2 to 100)100 (81.5 to 100)100 (80.5 to 100)100 (81.5 to 100)
Mo 6 (Arm A N=12, B N=16, C N=15, D N=17)100 (73.5 to 100)93.8 (69.8 to 99.8)100 (78.2 to 100)100 (80.5 to 100)
SecondaryPercentage of Participants With Suppression of Testosterone in <30 ng/dL by Visit

Percentage of participants with suppression of testosterone, out of the number of boys with at least 1 testosterone measurement at each visit (n/N%). Only boys are analyzed in this outcome measure. Observed data were used with no imputation for missing data.

Time frame:
Month 1, 2, 3 and 6
Reported as:
Number · Percentage of Participants
Percentage of Participants With Suppression of Testosterone in <30 ng/dL by Visit
Percentage of ParticipantsLeuprolide Acetate 11.25 mg - Treatment NaiveLeuprolide Acetate 11.25 mg - Previous TreatmentLeuprolide Acetate 30 mg - Treatment NaiveLeuprolide Acetate 30 mg - Previous Treatment
Mo 1 (Arm A N=2, B N=1, C N=2, D N=3)50.0 (1.3 to 98.7)100 (2.5 to 100)100 (15.8 to 100)100 (29.2 to 100)
Mo 2 (Arm A N=2, B N=1, C N=2, D N=3)50.0 (1.3 to 98.7)100 (2.5 to 100)100 (15.8 to 100)100 (29.2 to 100)
Mo 3 (Arm A N=2, B N=1, C N=2, D N=3)50.0 (1.3 to 98.7)100 (2.5 to 100)100 (15.8 to 100)100 (29.2 to 100)
Mo 6 (Arm A N=1, B N=1, C N=2, D N=3)100 (2.5 to 100)100 (2.5 to 100)100 (15.8 to 100)100 (29.2 to 100)
SecondaryPeak-stimulated Luteinizing Hormone Concentration by Visit

Observed data were used with no imputation for missing data.

Time frame:
Baseline, Month 1, 2, 3 and 6
Reported as:
Mean · mIU/mL
Peak-stimulated Luteinizing Hormone Concentration by Visit
mIU/mLLeuprolide Acetate 11.25 mg - Treatment NaiveLeuprolide Acetate 11.25 mg - Previous TreatmentLeuprolide Acetate 30 mg - Treatment NaiveLeuprolide Acetate 30 mg - Previous Treatment
Baseline (Arm A N=21, B N=21, C N=21, D N=21)45.9 ± 42.381.8 ± 1.7823.5 ± 16.761.7 ± 1.09
Mo 1 (Arm A N=21, B N=21, C N=21, D N=21)4.4 ± 7.291.7 ± 1.361.9 ± 1.741.4 ± 0.76
Mo 2 (Arm A N=21, B N=20, C N=21, D N=20)4.5 ± 7.202.0 ± 1.482.0 ± 2.251.5 ± 0.73
Mo 3 (Arm A N=16, B N=20, C N=20, D N=21)2.3 ± 1.231.8 ± 1.101.4 ± 0.781.5 ± 0.61
Mo 6 (Arm A N=15, B N=18, C N=18, D N=21)2.0 ± 0.852.5 ± 2.431.6 ± 0.951.5 ± 0.89
SecondaryPercentage of Participants With Suppression of the Physical Signs of Puberty (Breast Development) at Month 6

Percentage of participants with suppression of breast development, out of the number of girls with pubertal staging of breast development (n/N%). Only girls are analyzed in this outcome measure. Breast development was rated from Stage 1 (early development) through Stage 5 (full development) according to a Tanner Staging pictogram. Girls entering the study with fully developed breasts (Stage 5) were excluded from this analysis. Observed data were used with no imputation for missing data.

Time frame:
Month 6
Reported as:
Number · Percentage of Participants
Percentage of Participants With Suppression of the Physical Signs of Puberty (Breast Development) at Month 6
Percentage of ParticipantsLeuprolide Acetate 11.25 mg - Treatment NaiveLeuprolide Acetate 11.25 mg - Previous TreatmentLeuprolide Acetate 30 mg - Treatment NaiveLeuprolide Acetate 30 mg - Previous Treatment
Percentage of Participants With Suppression of the Physical Signs of Puberty (Breast Development) at Month 692.9 (66.1 to 99.8)88.9 (65.3 to 98.6)82.4 (56.6 to 96.2)82.4 (56.6 to 96.2)
SecondaryPercentage of Participants With Suppression of the Physical Signs of Puberty (Testicular Volume and Genital Development) at Month 6

Percentage of participants with suppression of genital development and testicular volume, out of the number of boys with pubertal staging of genital development or testicular volume (n/N%). Only boys are analyzed in this outcome measure. External genital development (testes and penis) was rated from Stage 1 (early development) through Stage 5 (full development) according to a Tanner Staging pictogram. Boys entering the study with fully developed genitals (Stage 5) were excluded from this analysis. Observed data were used with no imputation for missing data.

Time frame:
Month 6
Reported as:
Number · Percentage of Participants
Percentage of Participants With Suppression of the Physical Signs of Puberty (Testicular Volume and Genital Development) at Month 6
Percentage of ParticipantsLeuprolide Acetate 11.25 mg - Treatment NaiveLeuprolide Acetate 11.25 mg - Previous TreatmentLeuprolide Acetate 30 mg - Treatment NaiveLeuprolide Acetate 30 mg - Previous Treatment
Percentage of Participants With Suppression of the Physical Signs of Puberty (Testicular Volume and Genital Development) at Month 6100 (2.5 to 100)0 (0.0 to 97.5)50 (1.3 to 98.7)33.3 (0.8 to 90.6)
SecondaryChange From Baseline in Incremental Growth Rate (cm/Year) at Month 6

The growth rate at baseline was the growth rate during the last year before the start of treatment and was calculated with the measurement closest to Day -336 (before Day -30) and the measurement up to Day 1. Growth rate at Month 6 was defined as the ratio of the change in height from Day 1 to the change in chronological age, with an approximate 6-month interval between the 2 height measurements. Observed data were used with no imputation for missing data.

Time frame:
Baseline and Month 6
Reported as:
Mean · cm/year
Change From Baseline in Incremental Growth Rate (cm/Year) at Month 6
cm/yearLeuprolide Acetate 11.25 mg - Treatment NaiveLeuprolide Acetate 11.25 mg - Previous TreatmentLeuprolide Acetate 30 mg - Treatment NaiveLeuprolide Acetate 30 mg - Previous Treatment
Baseline (Arm A N=20, B N=21, C N=21, D N=21)7.25 ± 5.306.58 ± 2.397.83 ± 5.966.05 ± 1.55
Mo 6 (Arm A N=14, B N=19, C N=19, D N=21)-2.51 ± 5.29-0.98 ± 2.24-2.34 ± 4.22-0.91 ± 2.45
Statistical analysis
  • Leuprolide Acetate 11.25 mg - Treatment Naive · t-test, 2 sided · p = 0.099 (There were no adjustments for multiple comparisons.)
  • Leuprolide Acetate 11.25 mg - Previous Treatment · t-test, 2 sided · p = 0.074 (There were no adjustments for multiple comparisons.)
  • Leuprolide Acetate 30 mg - Treatment Naive · t-test, 2 sided · p = 0.026 (There were no adjustments for multiple comparisons.)
  • Leuprolide Acetate 30 mg - Previous Treatment · t-test, 2 sided · p = 0.102 (There were no adjustments for multiple comparisons.)
SecondaryRatio of Change From Baseline in Bone Age/Change From Baseline in Chronological Age at Month 6

The ratio at Month 6 was calculated as (bone age at Month 6 - bone age at baseline)/(chronological age at Month 6 - chronological age at baseline). Observed data were used with no imputation for missing data. Baseline bone-age radiograph was performed at or within 3 months of the Screening Visit.

Time frame:
Baseline to Month 6
Reported as:
Mean · Ratio
Ratio of Change From Baseline in Bone Age/Change From Baseline in Chronological Age at Month 6
RatioLeuprolide Acetate 11.25 mg - Treatment NaiveLeuprolide Acetate 11.25 mg - Previous TreatmentLeuprolide Acetate 30 mg - Treatment NaiveLeuprolide Acetate 30 mg - Previous Treatment
Ratio of Change From Baseline in Bone Age/Change From Baseline in Chronological Age at Month 60.59 ± 0.590.50 ± 0.571.00 ± 0.741.07 ± 1.60
Statistical analysis
  • Leuprolide Acetate 11.25 mg - Treatment Naive · Wilcoxon (Mann-Whitney) · p = 0.008 (There were no adjustments for multiple comparisons.)
  • Leuprolide Acetate 11.25 mg - Previous Treatment · Wilcoxon (Mann-Whitney) · p = 0.002 (There were no adjustments for multiple comparisons.)
  • Leuprolide Acetate 30 mg - Treatment Naive · Wilcoxon (Mann-Whitney) · p = 0.347 (There were no adjustments for multiple comparisons.)
  • Leuprolide Acetate 30 mg - Previous Treatment · Wilcoxon (Mann-Whitney) · p = 0.150 (There were no adjustments for multiple comparisons.)
Post-hocPercentage of Participants With Suppression of Peak Stimulated Luteinizing Hormone (< 4 mIU/mL) From Month 2 Through Month 6 (Simple Percentage With Binomial Exact Confidence Intervals)

Percentage of participants with suppression of peak stimulated luteinizing hormone that was measured after a GnRHa stimulation test at Mo 2, 3, and 6. A simple percentage and binomial exact confidence intervals were used in this analysis. Participants who withdrew with luteinizing hormone that remained suppressed were counted as a success. This analysis was performed after the clinical study report was completed and is included to match the FDA package insert.

Time frame:
Month 2 through 6
Reported as:
Number · Percentage of Participants
Percentage of Participants With Suppression of Peak Stimulated Luteinizing Hormone (< 4 mIU/mL) From Month 2 Through Month 6 (Simple Percentage With Binomial Exact Confidence Intervals)
Percentage of ParticipantsLeuprolide Acetate 11.25 mg - Treatment NaiveLeuprolide Acetate 11.25 mg - Previous TreatmentLeuprolide Acetate 30 mg - Treatment NaiveLeuprolide Acetate 30 mg - Previous Treatment
Percentage of Participants With Suppression of Peak Stimulated Luteinizing Hormone (< 4 mIU/mL) From Month 2 Through Month 6 (Simple Percentage With Binomial Exact Confidence Intervals)76.2 (52.8 to 91.8)81.0 (58.1 to 94.6)90.5 (69.6 to 98.8)100.0 (83.9 to 100.0)
Post-hocPercentage of Participants With a Decrease From Baseline in the Ratio of Bone Age to Chronological Age at Month 6 Compared to Baseline

The ratio at baseline or Month 6 was calculated as bone age at baseline or Month 6/chronological age at baseline or Month 6. The percentage of participants with a decrease in the ratio was calculated as a simple percentage for each dose group. Observed data were used with no imputation for missing data. The baseline time frame was increased from the secondary outcome in this analysis to include all participants with a bone age radiograph at screening. This analysis was performed after the clinical study report was completed \& is included to match the FDA package insert.

Time frame:
Baseline to Month 6
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Decrease From Baseline in the Ratio of Bone Age to Chronological Age at Month 6 Compared to Baseline
Percentage of ParticipantsLeuprolide Acetate 11.25 mgLeuprolide Acetate 30 mg
Percentage of Participants With a Decrease From Baseline in the Ratio of Bone Age to Chronological Age at Month 6 Compared to Baseline87.975.0

Adverse events

Collected over Treatment-emergent adverse events were defined as any event with an onset data after the first dose of study drug and with an onset date no more than 30 days after the last day of study drug treatment which is 84 days after the last injection date.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Leuprolide Acetate 11.25 mg - Treatment Naive—1/21 (4.8%)13/21 (61.9%)
Leuprolide Acetate 11.25 mg - Previous Treatment—0/21 (0%)18/21 (85.7%)
Leuprolide Acetate 30 mg - Treatment Naive—0/21 (0%)15/21 (71.4%)
Leuprolide Acetate 30 mg - Previous Treatment—1/21 (4.8%)17/21 (81%)
Most frequent serious events
Most frequent serious events
EventLeuprolide Acetate 11.25 mg - Treatment NaiveLeuprolide Acetate 11.25 mg - Previous TreatmentLeuprolide Acetate 30 mg - Treatment NaiveLeuprolide Acetate 30 mg - Previous Treatment
DepressionPsychiatric disorders1/210/210/210/21
NauseaGastrointestinal disorders0/210/210/211/21
Weight DecreasedGastrointestinal disorders0/210/210/211/21
VomitingGastrointestinal disorders0/210/210/211/21
DiarrheaGastrointestinal disorders0/210/210/211/21
Most frequent other events
Showing 10 of 23
Most frequent other events
EventLeuprolide Acetate 11.25 mg - Treatment NaiveLeuprolide Acetate 11.25 mg - Previous TreatmentLeuprolide Acetate 30 mg - Treatment NaiveLeuprolide Acetate 30 mg - Previous Treatment
Injection Site PainGeneral disorders4/214/214/217/21
PyrexiaGeneral disorders2/212/212/216/21
HeadacheNervous system disorders1/214/216/216/21
CoughRespiratory, thoracic and mediastinal disorders1/214/212/215/21
VomitingGastrointestinal disorders0/211/214/211/21
NasopharyngitisInfections and infestations1/214/211/211/21
Nasal congestionRespiratory, thoracic and mediastinal disorders3/211/214/211/21
Upper Respiratory Tract InfectionInfections and infestations2/213/213/212/21
Respiratory DisordersRespiratory, thoracic and mediastinal disorders0/213/210/210/21
RhinorrheaRespiratory, thoracic and mediastinal disorders1/210/210/213/21

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Leuprolide Acetate 11.25 mg - Treatment NaiveLeuprolide Acetate 11.25 mg - Previous TreatmentLeuprolide Acetate 30 mg - Treatment NaiveLeuprolide Acetate 30 mg - Previous TreatmentTotal
<=18 years2121212184
Between 18 and 65 years00000
>=65 years00000
Age Continuous
Age Continuous(Years)Leuprolide Acetate 11.25 mg - Treatment NaiveLeuprolide Acetate 11.25 mg - Previous TreatmentLeuprolide Acetate 30 mg - Treatment NaiveLeuprolide Acetate 30 mg - Previous TreatmentTotal
Mean7.4 ± 1.478.1 ± 1.837.3 ± 1.748.4 ± 1.757.8 ± 1.73
Sex: Female, Male
Sex: Female, Male(Participants)Leuprolide Acetate 11.25 mg - Treatment NaiveLeuprolide Acetate 11.25 mg - Previous TreatmentLeuprolide Acetate 30 mg - Treatment NaiveLeuprolide Acetate 30 mg - Previous TreatmentTotal
Female1920191876
Male21238
Region of Enrollment
Region of Enrollment(Participants)Leuprolide Acetate 11.25 mg - Treatment NaiveLeuprolide Acetate 11.25 mg - Previous TreatmentLeuprolide Acetate 30 mg - Treatment NaiveLeuprolide Acetate 30 mg - Previous TreatmentTotal
North America2121212184
08

Study locations

25 sites
  • Site Reference ID/Investigator# 8765
    Birmingham, Alabama 35233, United States
  • Site Reference ID/Investigator# 11522
    Long Beach, California 90806, United States
  • Site Reference ID/Investigator# 8756
    Los Angeles, California 90027, United States
  • Site Reference ID/Investigator# 8755
    San Diego, California 92123, United States
  • Site Reference ID/Investigator# 8761
    San Diego, California 92123, United States
  • Site Reference ID/Investigator# 8772
    Stanford, California 94305-5208, United States
  • Site Reference ID/Investigator# 8749
    Greenwood Village, Colorado 80111, United States
  • Site Reference ID/Investigator# 8771
    Gainesville, Florida 32608, United States
  • Site Reference ID/Investigator# 8764
    Jacksonville, Florida 32207, United States
  • Site Reference ID/Investigator# 17621
    Pensacola, Florida 32504, United States
  • Site Reference ID/Investigator# 8752
    Indianapolis, Indiana 46202, United States
  • Site Reference ID/Investigator# 8766
    Shreveport, Louisiana 71103, United States
  • Site Reference ID/Investigator# 8768
    Minneapolis, Minnesota 55455, United States
  • Site Reference ID/Investigator# 17341
    St. Paul, Minnesota 55102, United States
  • Site Reference ID/Investigator# 8759
    Kansas City, Missouri 64108, United States
  • Site Reference ID/Investigator# 8750
    Oklahoma City, Oklahoma 73104, United States
  • Site Reference ID/Investigator# 8760
    Tulsa, Oklahoma 74135, United States
  • Site Reference ID/Investigator# 8763
    Hershey, Pennsylvania 17033, United States
  • Site Reference ID/Investigator# 8754
    Salt Lake City, Utah 84108, United States
  • Site Reference ID/Investigator# 8762
    Seattle, Washington 98104, United States
  • Site Reference ID/Investigator# 8753
    Seattle, Washington 98105, United States
  • Site Reference ID/Investigator# 17922
    Bayamon, 00960, Puerto Rico
  • Site Reference ID/Investigator# 17923
    Ponce, 00717-2116, Puerto Rico
  • Site Reference ID/Investigator# 18242
    San Juan, 00936-5067, Puerto Rico
  • Site Reference ID/Investigator# 19661
    San Juan, 00936-8344, Puerto Rico
09

References and documents

Publications

  • Lee PA, Klein K, Mauras N, Neely EK, Bloch CA, Larsen L, Mattia-Goldberg C, Chwalisz K. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab. 2012 May;97(5):1572-80. doi: 10.1210/jc.2011-2704. Epub 2012 Feb 16. PubMed 22344198 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Jan 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2008
First posted
Mar 14, 2008
Start
Jun 2008
Primary completionActual
Jan 2010
CompletionActual
Jun 2010
Results first posted
Feb 9, 2011
Last update
Nov 2, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00635817
Lead sponsor
Abbott
Responsible party
Sponsor
First posted
Mar 14, 2008
Start date
Jun 2008
Primary completion
Jan 2010
Completion
Jun 2010
Results posted
Feb 9, 2011
Last update
Nov 2, 2011

Study contacts

Peter Bacher, MD,
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion